Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADI + BJOE is a combination therapy used in Chinese oncology, consisting of Aidi injection (ADI) and Brucea javanica oil emulsion (BJOE). ADI is a complex botanical injection typically containing extracts from *Panax ginseng*, *Astragalus membranaceus*, *Acanthopanax senticosus*, and cantharidin (derived from *Mylabris*). BJOE is an emulsion derived from the fatty oil of *Brucea javanica* seeds. This combination is primarily utilized for patients with advanced malignancies, such as colorectal, lung, and liver cancers, particularly those who cannot tolerate standard chemotherapy. It functions by inducing tumor cell apoptosis, inhibiting angiogenesis, and suppressing cell proliferation, while also mitigating chemotherapy-induced adverse effects like leukopenia and gastrointestinal toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aidi injection + brucea javanica oil emulsion.